Shares of Danaher Corporation (NYSE:DHR) have been given a consensus recommendation of “Buy” by the nineteen brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $93.55.
A number of analysts have issued reports on DHR shares. Zacks Investment Research downgraded Danaher Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, July 27th. Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $83.00 price objective on shares of Danaher Corporation in a research note on Tuesday, September 26th. Credit Suisse Group lifted their price objective on Danaher Corporation from $93.00 to $96.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $95.00 price objective on shares of Danaher Corporation in a research note on Friday, September 8th. Finally, Robert W. Baird lifted their price objective on Danaher Corporation from $87.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, October 20th.
Danaher Corporation (NYSE:DHR) traded up $0.50 during trading hours on Thursday, reaching $94.18. The company’s stock had a trading volume of 1,577,715 shares, compared to its average volume of 2,657,040. The company has a current ratio of 1.43, a quick ratio of 1.00 and a debt-to-equity ratio of 0.42. Danaher Corporation has a 1-year low of $76.27 and a 1-year high of $94.22. The company has a market cap of $65,340.00, a P/E ratio of 23.99, a price-to-earnings-growth ratio of 2.22 and a beta of 1.02.
Danaher Corporation (NYSE:DHR) last released its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. Danaher Corporation had a return on equity of 11.29% and a net margin of 13.36%. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.47 billion. During the same quarter in the previous year, the company posted $0.87 EPS. The company’s revenue was up 9.6% compared to the same quarter last year. equities research analysts expect that Danaher Corporation will post 3.99 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Shareholders of record on Friday, September 29th were given a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend was Thursday, September 28th. Danaher Corporation’s dividend payout ratio (DPR) is presently 16.67%.
WARNING: “Brokerages Set Danaher Corporation (DHR) Price Target at $93.55” was posted by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://transcriptdaily.com/2017/11/22/brokerages-set-danaher-corporation-dhr-price-target-at-93-55.html.
In other Danaher Corporation news, insider William King sold 43,688 shares of the company’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $82.86, for a total value of $3,619,987.68. Following the transaction, the insider now owns 45,748 shares of the company’s stock, valued at approximately $3,790,679.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Robert S. Lutz sold 11,189 shares of the company’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. Insiders sold a total of 317,498 shares of company stock worth $28,838,801 in the last ninety days. 12.20% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently made changes to their positions in DHR. BlackRock Inc. grew its position in Danaher Corporation by 2,530.9% in the 1st quarter. BlackRock Inc. now owns 37,967,922 shares of the conglomerate’s stock valued at $3,247,398,000 after acquiring an additional 36,524,795 shares during the last quarter. Point72 Asset Management L.P. grew its position in Danaher Corporation by 276.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,626,865 shares of the conglomerate’s stock valued at $225,332,000 after acquiring an additional 1,929,751 shares during the last quarter. Flossbach Von Storch AG grew its position in Danaher Corporation by 44.7% in the 2nd quarter. Flossbach Von Storch AG now owns 5,782,019 shares of the conglomerate’s stock valued at $487,945,000 after acquiring an additional 1,785,810 shares during the last quarter. Vanguard Group Inc. grew its position in Danaher Corporation by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 40,967,631 shares of the conglomerate’s stock valued at $3,503,962,000 after acquiring an additional 1,530,015 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in Danaher Corporation by 16,410.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,485,901 shares of the conglomerate’s stock valued at $125,395,000 after acquiring an additional 1,476,901 shares during the last quarter. 75.56% of the stock is currently owned by institutional investors.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.